Compare Live Nation Entertainment, Inc. (LYV) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Revvity Inc — how do they compare? Live Nation Entertainment, Inc. trades at $184.91 (market cap $42.71B), while Revvity Inc trades at $115.92 (market cap $12.91B). The key difference: Live Nation Entertainment, Inc. is far larger — about 3.3× Revvity Inc's market cap, and Revvity Inc pays a 0.24% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| LYV | RVTY | |
|---|---|---|
Market Cap | $42.71B | $12.91B |
Sector | Industrials | Technology |
52-Week High | $186.59 | $117.75 |
52-Week Low | $125.61 | $82.26 |
Enterprise Value | $44.92B | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation (LYV) trades at $184.65, showing minimal daily movement (+0.01%) amid strong analyst support with 87% buy ratings. The stock maintains a bullish technical outlook with key resistance at $186 and support at $181. Recent Q2 2026 earnings beat expectations with $1.05 EPS versus $0.66 estimate, driven by record concert attendance and international demand growth. Revenue reached $25.2B in 2025, though net margins remain thin at 0.51%.
The outlook remains positive given robust demand for live events and raised 2026 guidance, but high valuation multiples (P/E 117.5) and legal/regulatory risks warrant caution. Insider selling activity and negative ROE (-116.7%) highlight execution challenges despite strong top-line performance. Upside to consensus $209.54 target depends on margin expansion and debt management.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
